Purpose of Review: This review aims to provide a comprehensive overview of the diagnosis of brain death/death by neurologic criteria (BD/DNC) by emphasizing the clinical criteria established by the American Academy of Neurology (AAN) in light of their updated guidelines released in 2023. In this review, we will focus on the current implementation of ancillary tests including the catheter cerebral angiogram, nuclear scintigraphy, and transcranial Doppler, which provide support in diagnoses when clinical examination and apnea tests are inconclusive. Finally, we will also provide examples to discuss the implementation of certain imaging studies in the context of diagnosing BD/DNC. Recent Findings: Recent developments in the field of neurology have emphasized the importance of clinical criteria for diagnosing BD/DNC, with the AAN providing clear updated guidelines that include coma, apnea, and the absence of brainstem reflexes. Current ancillary tests, including the catheter cerebral angiogram, nuclear scintigraphy, and transcranial Doppler play a crucial role in confirming BD/DNC when the clinical assessment is limited. The role of commonly used imaging studies including computed tomography and magnetic resonance angiographies of the brain as well as CT/MR perfusion studies will also be discussed in the context of these new guidelines. Summary: BD/DNC represents the permanent cessation of brain functions, including the brainstem. This review article provides the historical context, clinical criteria, and pathophysiology that goes into making this diagnosis. Additionally, it explores the various ancillary tests and selected imaging studies that are currently used to diagnose BD/DNC under the newly updated AAN guidelines. Understanding the evolution of how to effectively use these diagnostic tools is crucial for healthcare professionals who encounter these BD/DNC cases in their practice.

Amyloidosis causes extracellular tissue deposition of insoluble polymeric protein fibrils. Insulin-derived amyloidosis (AIns) is a rare complication of insulin therapy, causing insulin accumulation at the repeated injection site, forming subcutaneous lumps. This causes impaired insulin absorption, affecting further glycemic management. Our patient had anterior abdominal soft tissue lesions and a biopsy concerning multiple myeloma. ¹⁸ F-FDG PET/CT done to evaluate any osseous/other extraosseous lesions demonstrated hypermetabolic lesions confined to the anterior abdomen. The mass was excised, and histopathology revealed insulin-derived amyloidoma. Per the literature search, only 1 previous case of AIns has been evaluated with PET/CT. PET/CT helps assess disease extent, localize, guide biopsy, and follow-up.